S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
Critical asset just had biggest fall on record (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Autozone stock price is still in the rally zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
Critical asset just had biggest fall on record (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Autozone stock price is still in the rally zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
Critical asset just had biggest fall on record (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Autozone stock price is still in the rally zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
Critical asset just had biggest fall on record (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Autozone stock price is still in the rally zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
NASDAQ:PACB

Pacific Biosciences of California (PACB) Stock Price, News & Analysis

$5.62
+0.39 (+7.46%)
(As of 02/27/2024 ET)
Today's Range
$4.97
$5.69
50-Day Range
$5.08
$10.36
52-Week Range
$4.97
$14.55
Volume
11.29 million shs
Average Volume
8.98 million shs
Market Capitalization
$1.50 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.90

Pacific Biosciences of California MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.62 Rating Score
Upside/​Downside
111.7% Upside
$11.90 Price Target
Short Interest
Healthy
12.78% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.31mentions of Pacific Biosciences of California in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$645,352 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.03) to ($0.86) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.95 out of 5 stars

Medical Sector

617th out of 944 stocks

Analytical Instruments Industry

17th out of 27 stocks


PACB stock logo

About Pacific Biosciences of California Stock (NASDAQ:PACB)

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

PACB Stock Price History

PACB Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
PacBio (PACB) Q4 Earnings Beat, Adjusted Gross Margin Down
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Earnings Preview: Pacific Biosciences
Pacific Biosciences of California Inc.
PacBio Prel. Q4 Revenue Surges, But Stock Down In Pre-market
See More Headlines
Receive PACB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacific Biosciences of California and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
2/27/2024
Next Earnings (Estimated)
5/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:PACB
CUSIP
69404D10
Employees
769
Year Founded
2004

Price Target and Rating

Average Stock Price Target
$11.90
High Stock Price Target
$17.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+111.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.62
Research Coverage
13 Analysts

Profitability

Net Income
$-306,730,000.00
Net Margins
-152.97%
Pretax Margin
-188.66%

Debt

Sales & Book Value

Annual Sales
$200.52 million
Book Value
$2.49 per share

Miscellaneous

Free Float
263,700,000
Market Cap
$1.50 billion
Optionable
Optionable
Beta
1.93

Social Links

These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. Christian O. Henry M.B.A. (Age 56)
    President, CEO & Director
    Comp: $1.1M
  • Ms. Susan G. KimMs. Susan G. Kim (Age 48)
    Chief Financial Officer
    Comp: $564.87k
  • Mr. Mark Van Oene (Age 51)
    Chief Operating Officer
    Comp: $772.11k
  • Mr. Jeff Eidel (Age 47)
    Chief Commercial Officer
    Comp: $435.62k
  • Dr. Stephen Turner (Age 56)
    Co-Founder & CTO
    Comp: $341.25k
  • Ms. Michele Farmer CPA (Age 44)
    VP & Chief Accounting Officer
  • Dr. Jonas Korlach Ph.D.
    Chief Scientific Officer
  • Trevin Rard
    Head of Investor Relations
  • Dr. Brett Atkins J.D.
    Ph.D., General Counsel & Corporate Secretary
  • Ms. Natalie Welch
    Chief People Officer














PACB Stock Analysis - Frequently Asked Questions

Should I buy or sell Pacific Biosciences of California stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last twelve months. There are currently 5 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PACB shares.
View PACB analyst ratings
or view top-rated stocks.

What is Pacific Biosciences of California's stock price target for 2024?

13 equities research analysts have issued twelve-month price objectives for Pacific Biosciences of California's stock. Their PACB share price targets range from $8.00 to $17.00. On average, they expect the company's stock price to reach $11.90 in the next twelve months. This suggests a possible upside of 111.7% from the stock's current price.
View analysts price targets for PACB
or view top-rated stocks among Wall Street analysts.

How have PACB shares performed in 2024?

Pacific Biosciences of California's stock was trading at $9.81 at the start of the year. Since then, PACB stock has decreased by 42.7% and is now trading at $5.62.
View the best growth stocks for 2024 here
.

When is Pacific Biosciences of California's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our PACB earnings forecast
.

How were Pacific Biosciences of California's earnings last quarter?

Pacific Biosciences of California, Inc. (NASDAQ:PACB) announced its quarterly earnings data on Thursday, February, 15th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.02. The biotechnology company earned $58.36 million during the quarter, compared to analyst estimates of $57.96 million. Pacific Biosciences of California had a negative trailing twelve-month return on equity of 40.26% and a negative net margin of 152.97%. Pacific Biosciences of California's revenue was up 113.3% on a year-over-year basis. During the same quarter last year, the business posted ($0.35) EPS.

What guidance has Pacific Biosciences of California issued on next quarter's earnings?

Pacific Biosciences of California issued an update on its fourth quarter 2023 earnings guidance on Monday, January, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $58.4 million-$58.4 million, compared to the consensus revenue estimate of $55.8 million.

What is Christian Henry's approval rating as Pacific Biosciences of California's CEO?

2 employees have rated Pacific Biosciences of California Chief Executive Officer Christian Henry on Glassdoor.com. Christian Henry has an approval rating of 100% among the company's employees. This puts Christian Henry in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pacific Biosciences of California own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Pfizer (PFE), Gilead Sciences (GILD), Illumina (ILMN), Novavax (NVAX), Advanced Micro Devices (AMD), AT&T (T), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Invitae (NVTA) and Tesla (TSLA).

Who are Pacific Biosciences of California's major shareholders?

Pacific Biosciences of California's stock is owned by a number of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (12.90%), Vanguard Group Inc. (10.02%), Sumitomo Mitsui Trust Holdings Inc. (4.94%), Nikko Asset Management Americas Inc. (4.94%), Jackson Square Partners LLC (3.63%) and Bellevue Group AG (2.74%). Insiders that own company stock include Christian O Henry, Kathy Ordonez, Michele Farmer, Oene Mark Van, Peter Fromen, Susan G Kim and William W Ericson.
View institutional ownership trends
.

How do I buy shares of Pacific Biosciences of California?

Shares of PACB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Pacific Biosciences of California have any subsidiaries?
The following companies are subsidiares of Pacific Biosciences of California: Circulomics, Omniome, PacBio Singapore PTE Limited, Pacific Biosciences (Shanghai) Co. Ltd., Pacific Biosciences Canada Limited, Pacific Biosciences Germany GmbH, Pacific Biosciences International LLC, Pacific Biosciences Japan GK, and Pacific Biosciences UK Limited.
Read More
This page (NASDAQ:PACB) was last updated on 2/28/2024 by MarketBeat.com Staff